ghk-cu clinical trial wound healing randomized ghk cu evidence as a multifunctional copper peptide: synthesis routes, process engineering and emerging applications | Systems Microbiology and Biomanufacturing Frontiers Buy GHK-Cu Copper Peptide |

Certain heart diseases can also cause palpitations

Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties

contains no bacteriostat, antimicrobial agent or preservative

In April 2026, the FDA removed BPC-157 from its Category 2 list (substances with safety concerns that were previously restricted from compounding)